BrainStorm Cell Therapeutics Downgraded to Hold by Maxim Group
ByAinvest
Thursday, Jul 24, 2025 12:32 am ET1min read
Maxim Group downgrades BrainStorm Cell Therapeutics (BCLI) from Buy to Hold, citing a shift in the company's valuation outlook. The average target price for BCLI is $15.17, with an upside of 2,163.50% from the current price of $0.67. The company has received FDA clearance to initiate a Phase 3b trial for NurOwn, but faces significant financial constraints and needs to secure proper funding to commence the trial.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet